[Therapeutic effect of recombinant interferon alpha on Takatsuki disease].
A case of Takatsuki disease, 57-year-old male associated with monoclonal IgA, lambda-type immunoglobulin was treated with recombinant alpha-interferon daily by intramuscular injection with an initial dose of 3 X 10(6) U/day. Four weeks later, gynecomastia was improved and breast pain disappeared. Increases of cholesterol from 84 mg/dl to 135 mg/dl and cholinesterase from 0.24 delta pH to 0.48 delta pH were observed, 8 weeks later. Though, there was no reduction in serum M protein, no decrease in the number of bone marrow tumor cell and no restoration of muscle atrophy and polyneuropathy. No predominant side effect was observed. We conclude that rIFN alpha has a some potential role in the treatment of Takatsuki disease and additional chemotherapy should be considered. Significance of the therapy against Takatsuki disease was discussed.
Morofuji
M
M
Department of Internal Medicine, Karatsu Red Cross Hospital.
Hirata
Y
Y
Ito
H
H
Okuma
K
K
Nakazato
Y
Y
Sumida
I
I
Hanada
M
M
Okamura
T
T
D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010265:Paraproteinemias / Q000628:therapy*; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins